BIOS MAKES MAJOR MOVE INTO
8 GLOBAL CLINICS VIA $21M
NEURAL RESEARCH PROJECT

Lady at a desk looking at neural data on a screen

Cambridge, UK – 3 November, 2022 – BIOS Health, a pioneer in the development of AI-driven precision medicine technology for decoding and treating the human nervous system, announced that its technology is moving into 8 worldwide clinics to power a ground-breaking new study funded by the US National Institutes of Health (NIH).

The NIH, the US Government’s national medical research agency, are funding a $21 million clinical programme called Research Evaluating Vagal Excitation and Anatomical Links (REVEAL). This will take place over three years, with world-leading partners including University of Minnesota, Mayo Clinic, Stanford University and BIOS. 

 

The main objective will be to collect and analyse neural data from 150 patients and investigate the potential for neural therapies, delivered electrically by pacemaker sized devices on the vagus nerve, to treat a wide range of chronic diseases including Heart Failure, Epilepsy, Arthritis, Respiratory conditions and many more. BIOS’ neural biomarker analysis capabilities are similar to the sequencing technologies used to analyse the genome but designed to capture and decode the complex signals present in human nerves. BIOS’ AI-driven software will be used to investigate the critical knowledge gaps in Vagus Nerve physiology and optimise new therapies in the cardiovascular, metabolic, immune, and autonomic nervous systems.

Abstract image showing how data from the nervous system is translated and then used for neuromodulation therapies, patient stratification and drug development

Fig 1. The BIOS neural interface converts raw neural data into actionable biomarkers

The resulting datasets will also form the foundations for the development of new drugs and medical devices to treat a wide range of chronic diseases related to the nervous system. The team behind the study hope it will have a similar impact on the field of medicines for human chronic disease as the Human Genome studies have had on treatments for cancer and rare disease.

The broader research consortium of eight industry and academic partners working on the REVEAL project will be led by the University of Minnesota and includes: Stanford University, the Mayo Clinic, MUSC Health, Washington University in St. Louis, and Sheppard Pratt alongside European and Australian centres such as the Scuola Superiore Sant’Anna in ItalyBRIGHT Research PartnersMonash University, and the Baker Heart and Diabetes Institute. In addition, existing FDA approved and commercially recognised implant devices will be provided by LivaNova for use in the trials. 

This will be the largest ever single clinical study of human neural data. We have partnered with world-class clinical and industrial organisations and BIOS will be instrumental in the success of the project - this is a major validation of BIOS’ platform and allows our technology to become the foundation of a next wave of precision neural medicines.

EMIL HEWAGE, CEO

BIOS HEALTH

The vagus nerve conveys continuous information from the brain to most organs in the body and vice versa. It has become increasingly clear that dysregulation of the vagus nerve underlies many chronic conditions. The REVEAL study is a major step forward in the new field of bioelectronic medicine which has the potential to completely change the way we treat many diseases related to the nervous system. We are excited about our partnership with BIOS Health and their AI software platform, which will enable us to rapidly translate masses of data and results from the REVEAL study into novel therapies for a variety of conditions from heart failure to epilepsy.

JOHN OSBORN, PROFESSOR OF SURGERY & PRINCIPAL INVESTIGATOR FOR THE REVEAL STUDY

UNIVERSITY OF MINNESOTA

The vagus nerve contains a wealth of health-related neural data and so the REVEAL study will allow us to discover new nerve-organ interactions in humans.  This study will be the largest ever effort to understand vagus nerve signals and chronic diseases and the BIOS neural biomarker platform will be the key to this effort.

OLIVER ARMITAGE, CSO

BIOS HEALTH

About BIOS Health

BIOS is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals. The human nervous system carries vast quantities of data and scientists have long known that faulty signals in the nervous system play a key role in driving chronic diseases. By understanding and correcting these signals in real time, BIOS can treat chronic illnesses in an effective, automated, and personalised way. BIOS has leveraged recent breakthroughs in AI and Machine Learning to translate the “language” of the nervous system for the first time. BIOS’ neural code is built on the world’s largest proprietary neural data set and is already in use clinically to enhance data from wearables used in remote chronic disease care.

Co-founded by Cambridge University graduates Emil Hewage, a computational neuroscientist, and Oliver Armitage, a biomechanical engineer, BIOS is made up of a wide range of experts from neuroscience, machine learning, software engineering, applied biomaterials, biotechnology, and medicine. The combined experience of the BIOS team extends to over 300 peer-reviewed publications, 10+ First of kind medical devices and 6k+ clinical procedures.
 

Media contact

Colette Cooley 

Marketing & Communications Executive

BIOS Health 

media@bios.health